
A Dose of Economics
Office of Health Economics 6 episodes Nov 17, 2026
A Dose of Economics is a health economics podcast hosted by Grace Hampson, a Director at the Office of Health Economics (OHE). Each episode features conversations with leading health economists, researchers, and policy experts on topics like HTA, NICE thresholds, cost-effectiveness, AMR, AI in health, drug shortages, and the future of healthcare decision-making. New episodes are released every Tuesday.
Episodes

Why one patient in the room isn’t enough
“Nothing about us, without us”. That’s how NICE expresses the principle of incorporating patient voices in healthcare decision making. But what does that look like in practice? Why does it matter? What’s the current state of play – and what could be done better? Grace Hampson is joined by Samantha Nier, Director of the Acute Leukemia Advocates Network (ALAN), and Chris Skedgel, Director at the Of

Undervalued and underused: why vaccines are losing ground
Vaccines are one of the most powerful tools in health, but uptake is not guaranteed and the value they create is often underestimated by policymakers and the public.Grace Hampson is joined by Stephan Lewandowski, Professor of Cognitive Science at the University of Bristol, and Simon Brassel, Associate Director at the Office of Health Economics, to explore why vaccination matters for individuals, h

Germany in the crosshairs: The latest on MFN pricing
In a bonus episode, Graham Cookson, CEO of the Office of Health Economics, goes into the most recent developments in US ‘Most Favoured Nation’ (MFN) pricing. Graham and Grace discuss the US pressure on Germany through a Section 301 investigation, what two recently published pharmaceutical company deals with the US government reveal about the policy’s aims, and how Europe and the rest of the worl

Why do medicines run out?
Drug shortages are no longer rare, isolated events. They have become a structural feature of the global pharmaceutical landscape. Grace Hampson is joined by Ross Maclagan, Head of Supply and Distribution Policy at the ABPI, and Amanda Cole, Director at the Office of Health Economics, to examine what causes medicine shortages, what they cost patients and health systems, and how policymakers should

The trade deal and the trade-offs
The UK-US trade deal put NICE’s cost-effectiveness threshold in the headlines, but is the threshold really the story? Grace Hampson is joined by Andy Briggs and Adrian Towse to examine what the change means for the cost of drugs, and how it interacts with total NHS medicines spending. A Dose of Economics is Grace and the Office of Health Economics (OHE) team thinking out loud, debating the quest

It’s not about working harder: rethinking NHS productivity
Healthcare productivity is a puzzle. Answers often focus on cost-cutting or adopting technology as quick wins. They miss the larger question: what does productivity in healthcare mean? Grace Hampson is joined by Anita Charlesworth, co-chair of the Health Foundation’s NHS Productivity Commission and Helen Hayes, Principal Economist at the Office of Health Economics to explore how to measure health

Individualised genetic therapies: A medicine for one
Individualised therapies are treatments developed for a single patient, or a small handful of patients. They can be life-saving or life-altering, often where nothing else exists. In 2018, Mila became the first person in the world to receive a medicine designed just for her. So why isn’t the broader development of these treatments for ultra-rare genetic diseases keeping pace with scientific advance

Net zero healthcare: Does HTA have a role to play?
Healthcare systems globally are responsible for nearly 5% of global greenhouse gas emissions. Understandably, many health systems have responded by setting net zero targets – but reaching those targets requires coordinated action across many parts of the healthcare ecosystem. As part of those efforts, should environmental impacts be taken into consideration when assessing the value of new health

Prevention works, so why don't we pay for it?
Prevention is often great value for money. And yet, countries all around the world are failing to properly invest in it, and their healthcare systems are paying the price. Grace Hampson is joined by Gundo Weiler, Director of Prevention and Health Promotion at the World Health Organization (WHO) Regional Office for Europe, and Graham Cookson, Chief Executive of the Office of Health Economics, to

Can HTA keep up with innovation?
Health technology assessment (HTA) is the process by which health systems evaluate whether new medicines, devices, and other interventions offer good value for money. But the pace of innovation often outruns policy -- new developments in innovative therapies, digital health technologies, and a shifting geopolitical landscape are pushing HTA systems to their limits. So are they still fit for purpos

Cost-effectiveness thresholds: theory, pragmatism, and NICE's new number
In April this year, NICE raised its cost-effectiveness threshold for the first time in 20 years, moving from £20,000-£30,000 per QALY to £25,000–£35,000 per QALY. On paper, it’s not a big difference. But the fact that there was a change, and how it came about, is significant. Grace Hampson is joined by Adrian Towse, who ran OHE as its Director for many years, and Chris Sampson, Senior Principal

What is your health worth? PROMs, EQ-5D & economic evaluation
How do we actually measure health? And in health economics, what is the difference between measuring health and assigning a value to it? Grace Hampson is joined by David Mott, Associate Director at OHE, as well as Hannah Hussain, an Economist at OHE, both part of OHE’s Measuring and Valuing Outcomes team. They’ll unpack how health economists measure and value health, and why getting this right ma











